ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)

THE PURPOSE OF THIS MODIFICATION IS TO 1. EXERCISE OPTION PERIOD 2 CLIN 0003 WITH A PERIOD OF PERFORMANCE OF JULY 22, 2025, TO DECEMBER 28, 2032, IN THE AMOUNT OF $38,697,183.73. AS A RESULT OF THIS MODIFICATION: 1. FUNDING IN THE AMOUNT OF $3

THE PURPOSE OF THIS MODIFICATION IS AS FOLLOWS: 1. CLIN 0008 (OPTION 7) THE TOTAL UNEXERCISED VALUE IS HEREBY DECREASED FROM $8,443,038.00 BY $1,554,748.99 TO $6,888,289.01 TO ACCOUNT FOR A DECREASE IN THE SCOPE OF WORK DUE TO THE SHORTER PERIOD OF

THE PURPOSE OF THIS MODIFICATION IS AS FOLLOWS: 1. CLIN 0001/ BASE: INCREASE THE FUNDING FROM $52,015,534.00 BY $4,695,621.32 TO $56,711,155.32 TO FACILITATE THE ONSHORING OF FILLED DOSE STORAGE, AS WELL AS SUPPORT PROCESS DEVELOPMENT STUDIES AIMED

THE PURPOSE OF THIS MODIFICATION IS HEREBY AMENDED AS FOLLOWS: 1. CLIN 0001 (BASE PERIOD) IS HEREBY AMENDED AS FOLLOWS: A. AN ADDITIONAL $17,053,156 IN FUNDS ARE BEING ALLOCATED TO ALLOW TO CONTINUE THE MANUFACTURING PROCESS DEVELOPMENT OF CHAD3-SU

THE PURPOSE OF THIS MODIFICATION IS TO CHANGE PRODUCTION UNDER CLIN 0005 AND CLIN 0006 AND EXTEND THE PERIOD OF PERFORMANCE ON CLIN 0005 AS FOLLOWS: 1. CLIN 0005 (OPTION 4) IS HEREBY AMENDED AS FOLLOWS: A. ADDITIONAL PRODUCT DEVELOPMENT EFFORTS ARE

ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.

ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.

ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.

THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI

ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.

THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI

ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.

ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.

ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.

ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.

ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.